Christopher Ashton
Director/Board Member en PEPGEN INC. .
Fortuna: - $ al 31/03/2024
Perfil
Christopher Philip Ashton is currently a Director at Pulmagen Therapeutics (Synergy) Ltd., a Director at OMass Therapeutics Ltd., an Independent Non-Executive Director at PepGen Inc., and an Advisor at Oxford Science Enterprises PLC.
Previously, he served as the Chief Executive Officer at Pulmagen Therapeutics (Synergy) Ltd., Etiologics Ltd., and Pulmagen Therapeutics LLP.
He was also the Chief Executive Officer at Achilles Therapeutics Plc from 2016 to 2018.
Additionally, he served as the Chairman at Macrophox Ltd.
from 2018 to 2020.
He has also worked as a Commercial Director at Galapagos Biotech Ltd.
and Oxford GlycoSciences Plc, and as a Partner at Syncona Partners LLP.
Ashton holds a doctorate degree from The University of Manchester.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PEPGEN INC.
-.--% | 22/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Christopher Ashton
| Empresas | Cargo | Inicio |
|---|---|---|
| PEPGEN INC. | Director/Board Member | 01/11/2020 |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | 07/10/2004 |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Consultant / Advisor | 31/12/2019 |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Director/Board Member | 14/10/2020 |
Antiguos cargos conocidos de Christopher Ashton.
| Empresas | Cargo | Fin |
|---|---|---|
Macrophox Ltd.
 Macrophox Ltd. BiotechnologyHealth Technology Macrophox Ltd. engages in the provision of research and experimental development on biotechnology. The company was founded on March 12, 2018 and is headquartered in Woodstock, The United Kingdom. | Chairman | 01/08/2020 |
| ACHILLES THERAPEUTICS PLC | Chief Executive Officer | 01/01/2018 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Chief Executive Officer | - |
Oxford GlycoSciences Plc
 Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Corporate Officer/Principal | - |
Formación de Christopher Ashton.
| The University of Manchester | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| PEPGEN INC. | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Empresas privadas | 9 |
|---|---|
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Oxford GlycoSciences Plc
Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Health Technology |
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
| Etiologics Ltd. | Commercial Services |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Commercial Services |
Macrophox Ltd.
Macrophox Ltd. BiotechnologyHealth Technology Macrophox Ltd. engages in the provision of research and experimental development on biotechnology. The company was founded on March 12, 2018 and is headquartered in Woodstock, The United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Christopher Ashton
